United States

Supernus Pharmaceuticals Inc (SUPN.OQ)

SUPN.OQ on NASDAQ Stock Exchange Global Market

3:59pm EST
Change (% chg)

$1.85 (+4.85%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Select another date:

Mon, Nov 6 2017

BRIEF-Supernus announces third quarter 2017 financial results

* Q3 earnings per share view $0.27 -- Thomson Reuters I/B/E/S

BRIEF-Supernus defeats second generic challenger to Oxtellar XR

* Supernus - Court ruled TWi Pharmaceuticals, unit infringed U.S. Patents by submitting to FDA, ANDA to market generic version of Oxtellar XR Source text for Eikon: Further company coverage:

BRIEF-Supernus Q2 earnings per share $0.32

* Supernus announces record second quarter 2017 financial results

BRIEF-Supernus says Shire receives FDA approval for Mydayis for ADHD

* Supernus announces that its partner Shire receives FDA approval for Mydayis™ for ADHD

Select another date: